Here are some of the top stories affecting key drug and biotech stocks that have links through to more in-depth coverage and analysis today at the website BioHealthInvestor.com: Rigel Pharmaceuticals Inc.’s (NASDAQ: RIGL) Phase IIb trial results Thursday morning of its rheumatoid arthritis candidate R788, is boosting its stock on speculation it may help the company [[ This is a content summary only. Visit my website for full links, other content, and more! ]]

Click here to Read the whole article